



News Release

Suven Income at INR 2586 Mn; PAT at INR 613 Mn for the half year ended September 2017

HYDERABAD, INDIA (11 Nov' 2017) – SUVEN LIFE Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2017. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 11th Nov' 2017 at Hyderabad.

Financial Highlights for the Half year ended September' 2017:

Growth in revenue	INR 2586 Mn vs INR 2600 Mn - down by 0.54%
Growth in PAT	INR 613 Mn vs. INR 589 Mn - up by 4.01%
Growth in EBIDTA	INR 1010 Mn vs. INR 913 Mn - up by 10.56%

Financial Highlights for the 2nd Quarter ended September' 2017 (QoQ):

Growth in revenue	INR 1120 Mn vs INR 1466 Mn - down by 23.63%
Growth in PAT	INR 317 Mn vs. INR 295 Mn - up by 7.37%
Growth in EBIDTA	INR 501 Mn vs. INR 509 Mn - down by 1.54%

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of INR 277 Mn (10.70% on income) for the half year ended September 2017.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained, if any, in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive